Cost-effectiveness analysis (2013 US$ among a hypothetical cohort of 10,000 acutely ill medical inpatients at ACCP-defined VTE risk).

<p>*A negative value indicates cost saved.</p><p>^§ 95% of iterations fall between the low- and high-range.</p><p>ACCP, American College of Chest Physicians; bid, twice daily; IU, international units; qd, once daily; UFH, unfractionated heparin; VTE, venous thromboembolism.</p><p>Cost-effectiveness analysis (2013 US$ among a hypothetical cohort of 10,000 acutely ill medical inpatients at ACCP-defined VTE risk).</p

Probability of incident VTE and AEs within 30 days of hospital admission.

<p>AE, adverse event; Av., average; bid, twice daily; CT, computed tomography; DVT, deep vein thrombosis; HIT, heparin-induced thrombocytopenia; IU, international units; LMWH, low-molecular-weight heparin; P, probability; PE, pulmonary embolism; qd, once daily; UFH, unfractionated heparin; VTE, venous thromboembolism; V/Q, ventilation-perfusion.</p><p>Probability of incident VTE and AEs within 30 days of hospital admission.</p

Costs (2013 US$) associated with diagnosis and treatment of venous thromboembolism and treatment-related adverse events.

<p>*Including $16 in pharmacy and nursing costs assumed per administration.</p><p>Bid, twice daily; HIT, heparin-induced thrombocytopenia; IU, international units; qd, once daily; UFH, unfractionated heparin.</p><p>Costs (2013 US$) associated with diagnosis and treatment of venous thromboembolism and treatment-related adverse events.</p

Cost-effectiveness acceptability curve based on a Monte Carlo simulation (10,000 iterations).

<p>bid, twice daily; IU, international units; qd, daily; VTE, venous thromboembolism.</p

One-way sensitivity analyses to determine the threshold value of (A) the probability of PE after DVT without treatment; and (B) probability of death among PE patients who survived the period immediately after the acute event without treatment, among 10,000 acutely ill medical inpatients at ACCP-defined VTE risk.

<p>ACCP, American College of Chest Physicians; bid, twice daily; DVT, deep vein thrombosis; IU, international units; PE, pulmonary embolism; qd, daily; VTE, venous thromboembolism.</p

Estimated rates and numbers of deaths averted and associated cost savings, with adherence to VTE prophylaxis among medical inpatients at VTE risk in US acute care hospitals.

<p>ACCP, American College of Chest Physicians; bid, twice daily; ICER, incremental cost-effectiveness ratio; IU, international units; LMWH, low-molecular-weight heparin; qd, once daily; UFH, unfractionated heparin; VTE, venous thromboembolism.</p><p>Estimated rates and numbers of deaths averted and associated cost savings, with adherence to VTE prophylaxis among medical inpatients at VTE risk in US acute care hospitals.</p

Unadjusted and adjusted odds ratios for PE-related death in patients with acute symptomatic pulmonary embolism.

<p>Unadjusted and adjusted odds ratios for PE-related death in patients with acute symptomatic pulmonary embolism.</p

Adjusted odds ratios for all-cause and PE-specific mortality in haemodynamically stable patients with acute symptomatic pulmonary embolism.

<p>Adjusted odds ratios for all-cause and PE-specific mortality in haemodynamically stable patients with acute symptomatic pulmonary embolism.</p

Patient flow diagram.

<p>Patient flow diagram.</p

Recurrent symptomatic venous thromboembolism in patients with acute symptomatic pulmonary embolism, stratified by gender from the time of diagnosis.

<p>Recurrent symptomatic venous thromboembolism in patients with acute symptomatic pulmonary embolism, stratified by gender from the time of diagnosis.</p